Abstract
In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.
MeSH terms
-
Animals
-
Antibodies, Monoclonal, Humanized
-
Certolizumab Pegol
-
Clinical Trials as Topic / methods
-
Clinical Trials as Topic / trends
-
Crohn Disease / immunology
-
Crohn Disease / metabolism
-
Crohn Disease / therapy
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Polyethylene Glycols / therapeutic use*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin Fab Fragments
-
Tumor Necrosis Factor-alpha
-
Polyethylene Glycols
-
Certolizumab Pegol